Plasminogen activators in ischemic stroke: introduction.
作者信息
del Zoppo Gregory J
机构信息
Department of Medicine, University of Washington School of Medicine, Box 359756, Harborview Medical Center, 325 Ninth Avenue, Seattle, WA 98104, USA.
出版信息
Stroke. 2010 Oct;41(10 Suppl):S39-41. doi: 10.1161/STROKEAHA.110.595769.
Abstract
摘要
相似文献
1
Plasminogen activators in ischemic stroke: introduction.缺血性卒中中的纤溶酶原激活剂：引言
Stroke. 2010 Oct;41(10 Suppl):S39-41. doi: 10.1161/STROKEAHA.110.595769.
2
Reversing stroke in the 2010s: lessons from Desmoteplase In Acute ischemic Stroke-2 (DIAS-2).21世纪10年代的中风逆转：急性缺血性中风去氨普酶-2（DIAS-2）研究的经验教训
Stroke. 2009 Sep;40(9):3156-8. doi: 10.1161/STROKEAHA.109.559682. Epub 2009 Jul 16.
3
Clinical inquiries. When should patients with stroke receive thrombolytics?
J Fam Pract. 2004 Aug;53(8):656, 658-9.
4
Treatment of acute ischemic stroke, Part 1.急性缺血性脑卒中的治疗，第1部分。
J Am Pharm Assoc (Wash). 1996 Oct;NS36(10):571-2.
5
The concept of combination therapy in acute ischemic stroke.急性缺血性卒中联合治疗的概念。
Neurology. 1997 Nov;49(5 Suppl 4):S70-4. doi: 10.1212/wnl.49.5_suppl_4.s70.
6
Is intravenous recombinant plasminogen activator effective up to 4.5 h after onset of ischemic stroke?静脉注射重组组织型纤溶酶原激活剂在缺血性卒中发病后长达4.5小时是否有效？
Nat Clin Pract Cardiovasc Med. 2009 Mar;6(3):164-5. doi: 10.1038/ncpcardio1447. Epub 2009 Jan 20.
7
Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.发病 3 小时后给予静脉重组组织型纤溶酶原激活剂治疗缺血性脑卒中的Meta 分析。
Int J Stroke. 2011 Feb;6(1):25-32. doi: 10.1111/j.1747-4949.2010.00537.x.
8
[Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].[缺血性卒中的静脉溶栓治疗：治疗前景]
Rev Neurol (Paris). 2015 Dec;171(12):866-75. doi: 10.1016/j.neurol.2015.09.002. Epub 2015 Nov 10.
9
Overview: hyperacute rt-PA stroke treatment. The NINDS rt-PA Stroke Study Group.
J Neurosci Nurs. 1997 Dec;29(6):351-5. doi: 10.1097/01376517-199712000-00003.
10
本文引用的文献
1
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion.急性大脑中动脉闭塞后内源性纤溶酶原激活剂的快速差异表达
Stroke. 2001 Jun;32(6):1341-8. doi: 10.1161/01.str.32.6.1341.
2
Laminin degradation by plasmin regulates long-term potentiation.纤溶酶介导的层粘连蛋白降解调节长时程增强效应。
J Neurosci. 2000 Mar 1;20(5):2003-10. doi: 10.1523/JNEUROSCI.20-05-02003.2000.
3
Astrocyte regulation of endothelial tissue plasminogen activator in a blood-brain barrier model.血脑屏障模型中星形胶质细胞对内皮组织型纤溶酶原激活物的调节作用
J Cereb Blood Flow Metab. 1998 Dec;18(12):1316-24. doi: 10.1097/00004647-199812000-00006.
4
Degradation of human plasma and extracellular matrix fibronectin by tissue type plasminogen activator and urokinase.
Int J Biochem Cell Biol. 1996 Oct;28(10):1141-50. doi: 10.1016/1357-2725(96)00055-6.
5
The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.基质溶素、胶原酶、纤溶酶和乙酰肝素酶对人内皮细胞源核心蛋白聚糖的降解及结合的碱性成纤维细胞生长因子的释放
J Biol Chem. 1996 Apr 26;271(17):10079-86. doi: 10.1074/jbc.271.17.10079.
6
Extracellular proteolysis in the adult murine brain.成年小鼠大脑中的细胞外蛋白水解作用。
J Clin Invest. 1993 Aug;92(2):679-85. doi: 10.1172/JCI116637.
7
Biological and clinical aspects of plasminogen activator inhibitor type 2.
Blood. 1995 Dec 1;86(11):4007-24.
8
Cultured bovine endothelial cells produce both urokinase and tissue-type plasminogen activators.培养的牛内皮细胞可产生尿激酶和组织型纤溶酶原激活剂。
J Cell Biol. 1982 Sep;94(3):631-6. doi: 10.1083/jcb.94.3.631.
9
Studies on the kinetics of plasminogen activation by tissue plasminogen activator.组织型纤溶酶原激活剂激活纤溶酶原的动力学研究。
Biochim Biophys Acta. 1982 Jun 24;704(3):461-9. doi: 10.1016/0167-4838(82)90068-1.
10
Effects of trypsin and plasmin treatment of myelin on the myelin-associated glycoprotein and basic protein.胰蛋白酶和纤溶酶处理髓磷脂对髓磷脂相关糖蛋白和碱性蛋白的影响。
J Neurochem. 1984 Aug;43(2):582-5. doi: 10.1111/j.1471-4159.1984.tb00938.x.
Zotero 插件